Our ChlamyDerm Therapy is being developed against Chlamydia infection. Chlamydia plays a role in atherosclerosis. We have demonstrated in mice the decrease of both inflammation and Chlamydia bacterium in the lung after ChlamyDerm immunization.
Under-reporting of the global Chlamydia infection is substantial, because most people with chlamydia are not aware of their infections and do not seek to be tested. In addition, testing is not often done if patients are treated for symptoms. An estimated 2.8 million Americans are infected with chlamydia each year. If left untreated, a chlamydial infection can cause serious reproductive and other health problems with both short-term and long-term consequences.
Our Chlamyderm vaccine is based on our technology platform on DermaPrep, Antigeneering and nanomedicine formulation.